 |
|
|
|
reason -at- fightaging -dot- org
|
|
Recent Entries
Thyroid Function and Inherited Human Longevity
Longevity in the 21st Century, PowerPoint
Comparative Longevity in Ants
Cryonics, Process, and Preparation
"Hazy on the Topic of How Aging Relates to the Diseases of Old Age"
Taking a Look at Mitochondrial Repair Research
Fundraising for Mitochondrial Uncoupling Research
Anoxia Tolerance and Species Longevity
Second Meeting of the SENS Los Angeles Chapter on August 27th
A Selection of Singularity Summit 2010 Coverage
Another Good Sign for Induced Pluripotency
The Balancing Act of Longevity Research Advocacy
Artificial Intelligence and Engineered Longevity: the Better Tools Viewpoint
Escaping the Hand You Were Dealt
Impairment of Blood Vessels in the Brain Isn't a Good Thing
An Addendum on Solar Radiation, Reliability Theory, and Longevity
Twenty Minutes to Argue that Work on Radical Life Extension is Valid Research
Regeneration as Controlled Cancer
The Prospects for Generating Blood in Large Volumes, and as Needed
The Little Things Add Up Over Time
Archives (Monthly)
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004
November 2004
October 2004
September 2004
August 2004
July 2004
June 2004
May 2004
April 2004
March 2004
February 2004
January 2004
Creative Commons
Fight Aging! is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite Fight Aging! content in any way you see fit, the only requirements being that you (a) link to the original, (b) attribute the author, and (c) attribute Fight Aging!.
|
 |
|
|
|
Cancer stem cell theories offers the prospect that various types of cancer spawn from characteristic stem-cell-like initial populations. Cancer exists because random mutations that occur in our cells as a result of damage and age will eventually produce one of these prolific and damaging cell types, possibly by damaging an existing adult stem cell, or possibly by radically mutating a normal somatic cell. Cancer stem cells are hard to eradicate completely through old-style chemotherapy, radiotherapy, or surgery, which is why cancers tend to recur - all it takes is one remaining errant stem cell to rebuild the cancer anew. But the nature of cancer stem cells also means that they are the weak link: destroy them and the cancer cannot survive. Fortunately, identifying and safely destroying specific cell types based on their biochemical differences is a core focus for biotechnology research these days. This is one of the reasons I am confident that my generation will not suffer greatly from cancer in later life: the cancer-killing therapies of three decades from now will be very safe, very effective, and very cheap.
On this topic, I noticed a few recent articles on cancer stem cell research and development today, and thought I would share.
Possible Prostate Cancer Culprit:
"Think about cancer as a disease of stem cells," said study coauthor Owen Witte, a Howard Hughes Medical Institute investigator at the University of California, Los Angeles. Mutations in these cells can cause "normal stem cells to lose their regularized behavior and instead turn into an incipient cancer," he said. Like many other tissues in the body, prostate tissue is made up of several different kinds of cells, including a class called basal stem cells. Normally these cells divide to replenish prostate tissue, but sometimes they become cancerous. Instead of producing normal cells, these stem cells lead to tumors.
$11.5 million NIH Center grant funds novel cancer stem cell research:
"Targeting cancer stem cells, rather than cancer cells, is a completely new strategy for treating cancer," said Dr. Stephen Wong, director of the Center for Bioengineering and Informatics at The Methodist Hospital Research Institute and principal investigator for the grant study. "By attacking the cancer stem cell, we hope to eliminate cancer’s ability to grow, recur or metastasize."
Researchers identify a potential therapeutic target for brain cancer:
Recent studies have increased our understanding of cancer by elucidating some of the differences that exist between tumor cells among patients and even between distinct subsets of tumor cells within the same patient. Evidence suggests there are subgroups of cells - called cancer stem cells or tumor initiating cells - within tumors that are harder to kill with current therapies than other cells within these tumors. Cancer stem cells may in fact be more important to destroy than non-cancer stem cells because they may be responsible for metastasis and for tumor recurrence after therapy. Identifying therapies which specifically target cancer stem cells therefore hold great promise for effective and lasting treatment.
The original paper for that last item makes for interesting reading. You should take a look. But of course things are never as simple as we'd like them to be. Cancer stem cells may not be at the base of all cancers, and there are strong arguments that might lead us to expect this to be the case. This final article from earlier in the month delves into some of these complications.
Dissecting Cancer Stem Cell Theories:
The stochastic, or clonal evolution, model dictates that, "despite the heterogeneity (in cancer), cells of many different phenotypes are capable of proliferating extensively and forming new tumors," Dr. Morrison summarized. The cancer stem cell model, in contrast, says that "cancer stem cells are uniquely capable of proliferating extensively and forming new tumors, and that they go through an aberrant process of differentiation giving rise to phenotypically diverse cancer cells with a limited capacity to divide." Which of these two theories is correct seems to depend upon the type of cancer.
|
|
Posted by Reason
|
|
|
|
|
|
I do not remember where I read the statistics, but I think that wiping out cancer would increase life-span in the developed world by two years, while wiping out arterial diseases would add more than a decade. (If anyone knows where this data comes from or any contrary data tell me...)
Are their any similar innovations to declog the arteries that in the pipeline yet? What are the time horizons?
[Posted by: Aki_Izayoi at February 22, 2010 10:34 PM]
|
|
|
|
|
So far war on cancer had been a failure -- that is the conclusion of an article in SCEPTICAL INQUIRER magazine for january of this year. After U.S. government spent 109 billion bucks since 1971, cancer survivor rate improved only by five percent. Realistically it doesn't bode well for the future. And it shows that spending hundreds of billions of bucks doesn't necessarily solve health problems.
[Posted by: nikki at February 23, 2010 3:53 PM]
|
|
|
|
|
There is a more rational hypothesis than the CSC hypothesis, which does not have any documented evidence. Nobody knows the source of CSCs; there is no evidence for its potential to undergo asymmetric division. On the other hand, the neosis paradigm of carcinogenesis has documented proof You can find all about the neosis paradigm of carcinogenesis from the internet by googling for the words "Neosis + Rajaraman". Neosis is a novel mode of cell division involved in the birth and self-renewal of all types of cancers. Senescent cell is supposed to be a tumor suppressor; therefore, it has to escape senescence if it want to become tumorigenic. This is what happens during the birth of tumor cells. The mitotically non-viable polyploid genome of the senescent cell undergoes neosis with an intact nuclear envelope during karyokinesis, this involves Epithelial-mesenchymal transition, during which the chromatin modulation occurs giving rise to the mitotically viable genomes of the neotic offspring. We have shown that this process is repetitive producing newer Raju cells, the neotic offspring, with transient stemness. Thus neosis appears to be the morphological manifestation of the epithelial-mesenchymal transition, which precedes neosis. The cells escape senescence-induced mitotic catastrophe via Neosis.
[Posted by: Dr. R. Rajaraman at May 16, 2010 5:51 AM]
|
|
|
|
|
New evidence indicates that neosis executes Epithelial-Mesenchymal transition. This tells us that EMT is not just transition but transformation of cells. We also know that EMT involves the birth of new tumor initiating cells, termed Raju cells, which are produced every time a cell undergoes neosis. New evidence indicates that the so called Cancer Stem Cells are only short-lived as opposed to the original concept of the CSC hypothesis. Just as the EMT and the reverse process MET occurs several times during embryogenesis, tumor cells undergo several EMTs and METs during its growth, each time yielding newer Raju cells, with slightly different gene expression profiles. This will explain the confusion due to the CSC hypothesis, which would like us to believe that CSCs are a constant part of the tumor cells just like normal stem cells, with unlimited division potential.
[Posted by: Dr. R. Rajaraman at June 28, 2010 12:39 PM]
|
|
|
Post a comment; thoughtful, considered opinions are valued. Please note that comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.
|
|
 |